Scientific paper - Original scientific paper
MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia
Cancers, 13 (2021), 9; 2068. https://doi.org/10.3390/cancers13092068


Cite this document

Abramović, I., Vrhovec, B., Škara, L., Vrtarić, A., Nikolac Gabaj, N., Kuliš, T. ... Sinčić, N. (2021). MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers, 13. (9). doi: 10.3390/cancers13092068

Abramović, Irena, et al. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia." Cancers, vol. 13, no. 9, 2021. https://doi.org/10.3390/cancers13092068

Abramović, Irena, Borna Vrhovec, Lucija Škara, Alen Vrtarić, Nora Nikolac Gabaj, Tomislav Kuliš, Goran Štimac, et al. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia." Cancers 13, no. 9 (2021). https://doi.org/10.3390/cancers13092068

Abramović, I., et al. (2021) 'MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia', Cancers, 13(9). doi: 10.3390/cancers13092068

Abramović I, Vrhovec B, Škara L, Vrtarić A, Nikolac Gabaj N, Kuliš T, and sur.. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers [Internet]. 2021 April 25 [cited 2022 May 19];13(9). doi: 10.3390/cancers13092068

I. Abramović, et al., "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia", Cancers, vol. 13, no. 9, April 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:404575. [Accessed: 19 May 2022]

Please login to the repository to save this object to your list.